Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Breast J · 2020 · PMC7155112 · PMID 31448513

Europe PMC DOI

hedged sentence

0.0869

closest p · 1.7× alpha

0.0869

boldest claim

The sentences

did not reach statistical significanceP = .0869so close (0.05 < p ≤ 0.1)

While overall survival data are not yet mature for PALOMA‐2, median overall survival was increased in PALOMA‐3 (32.0 vs 24.7 months, hazard ratio, 0.75 [95% CI, 0.53–1.04]), though this did not reach statistical significance ( P = .0869).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.